ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1672

Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients

Najla Aljaberi1, Arjun Mathur2, Steffy Jose3, Theresa Hennard4, Angela Merritt1, Qing Ma5, James Rose5, Rashmi Sahay6, Chunyan Liu6, Scott Wenderfer7 and Hermine I Brunner8, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Divison of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, 6Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 7Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 8PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2020

Keywords: Biomarkers, Lupus nephritis, Pediatric rheumatology, Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Renal involvement in childhood-onset systemic lupus erythematosus (cSLE) is a major cause of morbidity and mortality. Current tools to identify lupus nephritis (LN) fall short compared to renal biopsy. The renal activity index in lupus (RAIL) was developed using 6 urinary biomarkers to reflect disease activity(1).

Purpose: To test the usefulness of the RAIL in the clinical setting to identify children with active LN.

Methods: Urine samples were collected cross-sectionally from cSLE patients at the time of active LN or routine clinic visit. Patients were classified into active LN, inactive LN or non-LN SLE based on results of a renal biopsy and/or absence of LN determined by routine urinalysis. The following urine biomarkers are included in the RAIL score (neutrophil gelatinase-associated lipocalin, ceruloplasmin, monocyte chemoattractant protein-1, adiponectin, hemopexin, kidney injury molecule-1, urinary protein and creatinine). Analysis was done by Enzyme-linked immunosorbent assay (ELISA) and nephelometry. RAIL scores were calculated per the defined algorithm. The accuracy of the RAIL score was compared between groups.

Results: Among 117 cSLE patients, 37 had active LN, 30 had inactive LN and 50 had no LN. Clinical characteristics and distribution of RAIL scores are outlined in Table 1. RAIL scores of inactive LN and no-LN group largely overlapped so they were combined in one group (Group 2) and compared to active LN (Group 1). The RAIL score was significantly higher in Group 1 vs Group 2 (median 0.7 vs -1.1 respectively, p< 0.0001). The RAIL score diagnostic accuracy was assessed in a multivariable regression model. Adjusting for patient’s age and extra-renal SLE activity index (SLEDAI) score, the RAIL score was associated with odds ratio of 2.16 (95%CI 1.4-3.3, p=0.001) for active LN vs. inactive LN and non-LN SLE. A receiver operating curve for a RAIL cut-off score of 0.35 produced an area under the curve of 0.9 (sensitivity 86%, specificity 84%) for active LN. A RAIL score < 0.35 had a negative likelihood ratio of 0.17. Further adjustment for urinary protein and creatinine did not significantly influence the results.

Conclusion: The RAIL score is highly accurate in distinguishing active LN identified by renal biopsy, from inactive LN and non-LN SLE. A score of 0.35 identifies cSLE patients who very likely have active LN.

Table 1. Clinical characteristics and distribution of RAIL scores among Group 1 (active LN) and Group 2 (inactive LN + non-LN SLE) patients.

Figure 1. Receiver Operating Curve (ROC) for the RAIL score in differentiating active LN (Group 1) from Inactive LN & non-LN SLE (Group 2).


Disclosure: N. Aljaberi, None; A. Mathur, None; S. Jose, None; T. Hennard, None; A. Merritt, None; Q. Ma, None; J. Rose, None; R. Sahay, None; C. Liu, None; S. Wenderfer, Bristol-Myers Squibb, 1; H. Brunner, Bristol-Myers Squibb, 2, 5, MedImmune, 2, Novartis, 2, 8, Pfizer Inc, 2, 5, AbbVie, 5, AstraZeneca-MedImmune, 5, Bayer, 5, Biocon, 5, Boehringer Ingelheim, 5, Janssen, 5, Eli Lilly, 5, R-Pharm, 5, Roche, 5, 8, Cincinnati Children’s Hospital Medical Center, 3, GlaxoSmithKline, 8.

To cite this abstract in AMA style:

Aljaberi N, Mathur A, Jose S, Hennard T, Merritt A, Ma Q, Rose J, Sahay R, Liu C, Wenderfer S, Brunner H. Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Childhood Systemic Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/renal-activity-index-for-lupus-nephritis-distinguishes-active-renal-disease-among-childhood-systemic-lupus-erythematosus-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-activity-index-for-lupus-nephritis-distinguishes-active-renal-disease-among-childhood-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology